Less Ads, More Data, More Tools Register for FREE

IP Group posts record results for 2013

Tue, 04th Mar 2014 09:07
Shares in IP Group, which develops intellectual property based businesses, rose strongly on Tuesday morning after the group posted a leap in adjusted pre-tax profit for the year ended December 31st. In a record year for FTSE 250-listed IP, earnings rose to £77.6m (2012: £46.7m), on revenue of £85.4m (2012: £52.5m). The company also revealed that its net assets had increased to £337.0m (2012: £263.1m), while the fair value of the portfolio grew to £285.9m (2012: £181.8m) across 72 companies. The value of its ten largest holdings increased to £225.2m, up from £138.2m a year earlier. Chief Executive Officer Alan Aubrey said: "2013 was a record year with the strongest financial performance since the group was formed in 2001. "The current year has started well with Actual Experience listing on AIM and Xeros Limited also announcing its intention to float on AIM [...]. We remain confident in the group's ability to deliver significant shareholder value."The group also said that during the year there had been "significant strategic progress" with a commercialisation agreement with the University of Manchester, an investment in Cambridge Innovation Capital, as well as pilot agreements with two of the US's eight Ivy League universities.Since the year-end the group has announced the recommended acquisition of the remaining 79.9% of Fusion IP that it does not currently own, which it has predicted will create a stronger UK-based IP commercialisation company with greater critical mass including a portfolio valued at over £300m and approximately £140m of cash.NR Ip Group

Shares in this article

Related News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

Corporate News Ip Group + 1 more share